SES
22.2.2024 14:26:26 CET | Business Wire | Press release
The Luxembourg Directorate of Defence (DoD) procured two ground stations following a competitive call for tender to enable the Luxembourg Army to improve its resilience by accessing secure satellite communications services, the DoD, SES and HITEC Luxembourg said today.
The ground stations, which will be installed at the Luxembourg Army’s Military Centre in Diekirch, will be used for Luxembourg’s GovSat-1 satellite services in X- and Military Ka-band frequencies, as well as for the Wideband Global Satcom (WGS) system, the backbone of the satellite communications capability of the U.S. DoD.
The addition of the two new ground stations reinforce resiliency and augment the existing Luxembourg Army satcom infrastructure already built by SES and HITEC Luxembourg 10 years ago, bringing the total number of dedicated antennas to four. The new ground stations unlock the strong potential to scale and add interoperability with the NATO partner systems, in line with the country’s defence strategy for the years to come.
Yuriko Backes, Luxembourg Minister of Defence: “Access to secure satellite communications has always been among the priorities and strengths of Luxembourg, allowing the country to reinforce defence capabilities, as well as enabling fulfillment of Luxembourg’s commitments towards the EU and NATO. To keep the upper technological edge, we will continue to leverage Luxembourg’s globally-renowned expertise in the space sector, to increase our resilience, including that of our armed forces.”
“It is an honour for SES to help strengthen the Luxembourg Government’s defence pillar by adding resiliency to its secure satcom,” said Adel Al-Saleh, CEO of SES. “Following the successful implementation of the initial ground stations by the Luxembourg Army, we are delighted to extend its communications infrastructure that leverages Luxembourg’s GovSat-1 and enhances interoperability with the partner systems.”
“We are proud to be part of the project and once again join efforts with SES to help augment Luxembourg’s defence capabilities with resilient and proven technology,” said Philippe Osch, CEO of HITEC Luxembourg. “The ground terminals to be supplied for the Luxembourg Army’s satcom infrastructure are a source of particular pride for us as they combine the latest technological innovations and a track-record of superior “Made in Luxembourg” quality.”
Follow us on:
Twitter | Facebook | YouTube | LinkedIn | Instagram
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless data connectivity services around the world. As a leader in global content connectivity solutions, SES owns and operates the world’s only geosynchronous orbit and medium earth orbit (GEO-MEO) constellation of satellites with the unique combination of global coverage and high performance. By leveraging its vast and intelligent, cloud-enabled network, SES delivers high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 6,400 channels, reaching 369 million households, delivering managed media services for both linear and non-linear content. The company is headquartered in Luxembourg and listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com
About HITEC Luxembourg
HITEC Luxembourg S.A., a 100%-owned Luxembourg company, has developed its business activities in the field of innovative and quality products and services.
HITEC offers high technology solutions covering different business areas: satellite ground segment; specific and standard equipment for testing and measuring of physical properties; traffic management; mission critical; engineering; consulting; software & ICT development and project management. HITEC serves private and public sector customers at a national and international level.
In our daily commitment, know-how, creativity, quality and perseverance are an integral part of HITECs’ undertaking. Enthusiasm for technology and innovation and a dedication to life-long-learning are core elements of our company culture, reflected by our highly qualified and motivated staff.
HITEC is ISO 9001, ISO 14001, ISO 45001 and AQAP 2110 certified and has several labels, such as “SuperDrecksKëscht fir Betriber“ (ISO 14024:2000 Standard), “Entreprise Socialement Responsable”, delivered by the indr, Responsibility Europe, Made in Luxembourg (for most of the products & services) and is signatory of the IMS Diversity Charter and the “Pacte National – Entreprises et Droits de l’Homme Luxembourg”. HITECs’ motto: market-oriented, client-centric and technology driven.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222299678/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom